Roivant Sciences had its Relative Strength (RS) Rating upgraded from 70 to 73 Friday — a welcome improvement, but still shy of the 80 or higher score you prefer to see.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Roivant Sciences can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Roivant Sciences is working on a cup with handle with a 12.94 entry. See if the stock can break out in heavy trade.
The company posted 0% EPS growth last quarter. Sales increased 23%.
The company holds the No. 134 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Neurocrine Biosciences are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
